Company Announcements

4 August 2025

ValiRx PLC

("ValiRx" or the "Company")

ValiRx Licensing Agreement with Dominion Biotech Ltd

London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to provide the following update on the commercial activity of its solely owned subsidiary Inaphaea BioLabs ("Inaphaea").

Inaphaea is pleased to announce the execution of an exclusive licence agreement (the "Agreement") with UK based Dominion Biotech Ltd ("Dominion") for Inaphaea's PredictRx® platform. PredictRx is a personalised cancer screening service whereby a patient's tumour sample is processed into Patient Derived Cells (PDCs) and subjected to a comprehensive drug combination screening panel to determine optimal chemotherapy treatment protocols.

Under the terms of the Agreement, Inaphaea will receive a 50% share of global net revenues from the PredictRx service to be offered by Dominion. Dominion and Inaphaea will also share ownership of any new Patient Derived Cells (PDCs) developed.  The Agreement is for a period of 2 years with annual renewal thereafter. Either party may initiate a buyout of the rights of the other party after an initial period of 18 months under pre-agreed terms based on a multiple of trailing net revenue. Although initial revenues under the Agreement are expected to be modest, the arrangement is strategically important in demonstrating the commercial application of ValiRx's platform and establishing future buyout value.

Mark Eccleston, CEO of ValiRx commented "We have expanded our relationship with Dominion as we continue to develop and commercialise Inaphaea's asset base. PredictRx is a pioneering, in-vitro approach for predicting drug sensitivity for cancer therapies at the individual patient level based on analysis of the patient's own cancer cells. This can deliver significant benefit by identifying the most effective treatment options leading to a truly personalised approach to therapy which ultimately should deliver improved outcomes for patients. Inaphaea's focus is translational drug development services and monetising of its biobank through its PDC models and through this license to Dominion which will develop and commercialise the PredictRx clinical service globally."

Anthony Holmes, CEO of Dominion commented "We're delighted to expand our successful partnership with Inaphaea by bringing the PredictRx platform to market globally. This innovative personalised cancer screening service represents a significant advancement in precision oncology - using a patient's own cancer cells to identify the most effective treatment options before therapy begins. By leveraging our established network of oncologists and patient-derived cell expertise, we can now offer clinicians and patients a powerful tool to optimise treatment decisions from day one. This licensing agreement demonstrates our commitment to translating cutting-edge science into real-world clinical benefits that can improve patient outcomes and potentially reduce the trial-and-error approach that too often characterises cancer treatment today."

The Directors of the Company take responsibility for this announcement.

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor
hub here: https://valirx.com/s/cc8ef3

For more information, please contact:

Subscribe to our news alert service: https://valirx.com/s/f298d1

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com